Treatment with Crexont statistically significantly improved “On” time without troublesome dyskinesia compared with carbidopa/levodopa IR. The Food and Drug Administration (FDA) has approved Crexont ® ...

The FDA approved Dhivy in November 2021 based upon bioavailability studies comparing Dhivy to an immediate-release tablet containing 25mg of carbidopa and 100mg of levodopa. Dhivy ™, a ...

Amneal to hold CREXONT launch symposium and scientific presentations at the International Congress of Parkinson’s Disease and Movement Disorders on Sept. 27 – Oct. 1, 2024 BRIDGEWATER, N.J.--(BUSINESS ...

SPID ®-Technology utilizes compartmentalization to enable sequential release of carbidopa and levodopa, offering a potential new approach for drug delivery in Parkinson’s disease treatment. "Levodopa ...

CREXONT added to 3 large national formularies: Veterans Administration, UnitedHealthcare and CVS Health Increases insurance coverage to over 50% of covered lives CREXONT was approved by the U.S. FDA ...

Please provide your email address to receive an email when new articles are posted on . The FDA has declined to approve Amneal Pharmaceuticals’ new drug application for IPX203, a novel, oral ...

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted a new drug application from Amneal Pharmaceuticals Inc. for IPX203, an oral formulation of ...

Delivers more “Good On” time with less frequent dosing compared to Immediate Release CD/LD Underscores Amneal’s leadership in Parkinson’s disease and commitment to one million people currently living ...

The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for ...

Foscarbidopa and foslevodopa are pro-drugs for carbidopa and levodopa, which are standard-of-care Parkinson's treatments. The new treatment, formerly know as ABBV-951, is the first subcutaneous ...

Carbidopa is in a class of medications called decarboxylase inhibitors which works by preventing levodopa from being broken down before it reaches the brain. The combination of levodopa and carbidopa ...